Effect of Out‐of‐Pocket Cost on Medication Initiation, Adherence, and Persistence among Patients with Type 2 Diabetes: The Diabetes Study of Northern California (DISTANCE)
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Objective: To estimate the effect of out‐of‐pocket (OOP) cost on nonadherence to classes of cardiometabolic medications among patients with diabetes. Data Sources/Setting: Electronic health records from a large, health care delivery system for 223,730 patients with diabetes prescribed 842,899 new cardiometabolic medications during 2006–2012. Study Design: Observational, new prescription cohort study of the effect of OOP cost on medication initiation and adherence. Data Collection: Adherence and OOP costs were based on pharmacy dispensing records and benefits. Principal Findings: Primary nonadherence (never dispensed) increased monotonically with OOP cost after adjusting for demographics, neighborhood socioeconomic status, Medicare, medical financial assistance, OOP maximum, deductibles, mail order pharmacy incentive and use, drug type, generic or brand, day's supply, and comorbidity index; 7 percent were never dispensed the new medication when OOP cost ≥$11, 5 percent with OOP cost of $1–$10, and 3 percent when the medication was free of charge (p < .0001). Higher OOP cost was also strongly associated with inadequate secondary adherence (≥20 percent of time without adequate medication). There was no clinically significant or consistent relationship between OOP costs and early nonpersistence (dispensed once, never refilled) or later stage nonpersistence (discontinued within 24 months). Conclusions: Cost‐sharing may deter clinically vulnerable patients from initiating essential medications, undermining adherence and risk factor control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Validation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587
Causal Diagrams for Epidemiologic Research
Greenland, S., Pearl, J., & Robins, J. M. (1999) · Epidemiology · doi:10.1097/00001648-199901000-00008 · Cited by 3,728
Ouellette, J. A., & Wood, W. (1998) · Psychological Bulletin · doi:10.1037/0033-2909.124.1.54 · Cited by 3,480
Hernan, M. A. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.2.176 · Cited by 1,445
Medication adherence: a call for action
Bosworth, H. B., Granger, B. B., Mendys, P., Brindis, R., Burkholder, R., Czajkowski, S. M., Daniel, J. G., Ekman, I., Ho, M., Johnson, M., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.007 · Cited by 448 · cited 2×
“While the bulk of evidence suggests that patients’ use of medicine is price-sensitive, adherence is also influenced by myriad noncost factors (Piette and Wagner 2006; Bosworth et al. 2011; Kirkman et al. 2015), including age, education, income (Berkowitz et al.”
BackgroundDeterminants of Adherence to Diabetes Medications: Findings From a Large Pharmacy Claims Database
Kirkman, M. S., Rowan-Martin, M. T., Levin, R., Fonseca, V. A., Schmittdiel, J. A., Herman, W. H., & Aubert, R. E. (2015) · Diabetes Care · doi:10.2337/dc14-2098 · Cited by 388 · cited 2×
“While the bulk of evidence suggests that patients’ use of medicine is price-sensitive, adherence is also influenced by myriad noncost factors (Piette and Wagner 2006; Bosworth et al. 2011; Kirkman et al. 2015), including age, education, income (Berkowitz et al.”
BackgroundEngler, D., Pham, T., Fullerton, M. J., Ooi, G., Funder, J. W., & Clarke, I. J. (2008) · Neuroendocrinology · doi:10.1159/000125141 · Cited by 235
A modified least-squares regression approach to the estimation of risk difference.
Cheung, Y. B. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm223 · Cited by 189
Intensive treatment and severe hypoglycemia among adults with type 2 diabetes
McCoy, R. G., Lipska, K. J., Yao, X., Ross, J. S., Montori, V. M., & Shah, N. D. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.2275 · Cited by 143
Piette, J. D., Heisler, M., Horne, R., & Caleb Alexander, G. (2006) · Social Science & Medicine · doi:10.1016/j.socscimed.2005.06.045 · Cited by 138
Cited by
Maddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Brouse, S., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.024 · Cited by 362
White-Williams, C., Rossi, L. P., Bittner, V. A., Driscoll, A., Durant, R. W., Granger, B. B., Graven, L. J., Kitko, L., Newlin, K., Shirey, M., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000767 · Cited by 349
Insulin Access and Affordability Working Group: Conclusions and Recommendations
Cefalu, W. T., Dawes, D. E., Gavlak, G., Goldman, D., Herman, W. H., Van Nuys, K., Powers, A. C., Taylor, S. I., Yatvin, A. L., & on behalf of the Insulin Access and Affordability Working Group (2018) · Diabetes Care · doi:10.2337/dci18-0019 · Cited by 256
Caraballo, C., Valero-Elizondo, J., Khera, R., Mahajan, S., Grandhi, G. R., Virani, S. S., Mszar, R., Krumholz, H. M., & Nasir, K. (2020) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.119.006139 · Cited by 104
Lipska, K. J., Parker, M. M., Moffet, H. H., Huang, E. S., & Karter, A. J. (2018) · JAMA · doi:10.1001/jama.2018.7993 · Cited by 76
Self-citationWeeda, E. R., Muraoka, A. K., Brock, M. D., & Cannon, J. M. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14060 · Cited by 73
National trends in pediatric admissions for diabetic ketoacidosis, 2006–2016
Everett, E. M., Copeland, T. P., Moin, T., & Wisk, L. E. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab287 · Cited by 38
Rodriguez, L. A., Finertie, H., Neugebauer, R. S., Gosiker, B., Thomas, T. W., Karter, A. J., Gilliam, L. K., Oshiro, C., An, J., Simonson, G., et al. (2024) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2024.100759 · Cited by 31
“24 A recent study reported out-of-pocket cost to be an independent predictor of SGLT2i and GLP1RA initiation irrespective of race and ethnicity while another showed racial and ethnic differences in anti-hyperglycemic medication initiation with narrower cost differences.”
BackgroundSelf-citationShah, E. D., Suresh, S., Jou, J., Chey, W. D., & Stidham, R. W. (2020) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000530 · Cited by 23
Luo, J., Feldman, R., Rothenberger, S., Korytkowski, M., Fischer, M. A., & Gellad, W. F. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07331-1 · Cited by 18
Predicting Self‐Reported Social Risk in Medically Complex Adults Using Electronic Health Data
Grant, R. W., McCloskey, J. K., Uratsu, C. S., Ranatunga, D., Ralston, J. D., Bayliss, E. A., & Sofrygin, O. (2024) · Medical Care · doi:10.1097/mlr.0000000000002021 · Cited by 4
Metadata
- Authors
- Karter, A. J., Parker, M. M., Solomon, M. D., Lyles, C. R., Adams, A. S., Moffet, H. H., & Reed, M. E.
- Venue
- Health Services Research
- Publisher
- Wiley
- Published
- 2017-05-05
- Volume
- 53
- Issue
- 2
- Pages
- 1227-1247
- ISSN
- 0017-9124 (ISSN-L)
- 1475-6773
- OpenAlex
- W2611203237
- Cited by
- 80
- References
- 12
- FWCI
- 6.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.